GlassScriptPhysician profile
Heather D Harle
NPI 1992919138
$4,278.10
in general payments reported to CMS, 2019-2025
36 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $253 · 2021: $307 · 2022: $198 · 2023: $1,168 · 2024: $791 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,113 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,112.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $854.98 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $350.36 | 2019-2024 | |
| Biogen, INC. | $299.88 | 2019-2024 | Vumerity |
| Ucb, INC. | $292.33 | 2022-2025 | Fintepla, Rystiggo, Briviact |
| Emd Serono, INC. | $231.65 | 2019-2023 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $211.54 | 2024-2025 | Ultomiris |
| Lundbeck LLC | $194.66 | 2021-2025 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $167.05 | 2020-2023 | Zeposia |
| Sk Life Science, INC. | $154.44 | 2021-2024 | Xcopri |
| Mdd US Operations, LLC | $148.24 | 2025 | Gocovri, Apokyn |
| Amgen INC. | $138.91 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $125.01 | 2023 | Amvuttra |
| Jazz Pharmaceuticals INC. | $125.00 | 2024 | |
| Neurocrine Biosciences, INC. | $122.60 | 2022-2025 | |
| Argenx US, INC. | $111.78 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $107.39 | 2020 | |
| Impel Pharmaceuticals INC. | $73.66 | 2023 | Trudhesa |
| Allergan, INC. | $59.92 | 2020 | |
| Celgene Corporation | $53.41 | 2022-2023 | Zeposia |
| Amneal Pharmaceuticals LLC | $50.73 | 2021-2025 | Crexont |
| Csl Behring | $49.61 | 2022 | |
| Pfizer INC. | $46.46 | 2024-2025 | |
| Tg Therapeutics, INC. | $45.20 | 2024 | |
| Genentech USA, INC. | $30.65 | 2023 | Ocrevus, Enspryng |
| Medtronic, INC. | $30.52 | 2023 | Linq II |
| Biohaven Pharmaceutical Holding Company LTD. | $29.15 | 2022 | |
| Impel Pharmaceuticals LLC | $27.43 | 2025 | Trudhesa |
| Acorda Therapeutics, INC | $23.54 | 2019 | |
| Lilly USA, LLC | $20.91 | 2019 | |
| Acadia Pharmaceuticals INC | $19.04 | 2025 | Nuplazid |
| Merz Pharmaceuticals, LLC | $17.70 | 2025 | Inbrija, Ampyra, Xeomin |
| Neurelis, INC. | $16.75 | 2023 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $16.56 | 2019 | |
| Livanova USA, INC. | $16.33 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Zyla Life Sciences, INC. | $10.99 | 2019 | |
| Supernus Pharmaceuticals, INC. | $3.72 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Harle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.